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Abstract
Background: A high neutrophil-to-lymphocyte ratio (NLR) may be related to increased mortality in patients with lung,
colorectal, stomach, liver, and pancreatic cancer. To date, the utility of NLR to predict the response to neoadjuvant
chemotherapy (NAC) has not been studied. The aim of our study was to determine whether the NLR is a predictor
of response to NAC and to investigate the prognostic impact of the NLR on relapse-free survival (RFS) and breast
cancer-specific survival (BCSS) in patients with breast cancer who received NAC.
Methods: We retrospectively studied patients who received NAC and subsequent surgical therapy for stage II–III
invasive breast carcinoma at Sun Yat-sen Memorial Hospital between 2001 and 2010. The correlation of NLR with the
pathological complete response (pCR) rate of invasive breast cancer to NAC was analyzed. Survival analysis was used
to evaluate the predictive value of NLR.
Results: A total of 215 patients were eligible for analysis. The pCR rate in patients with lower pretreatment NLR
(NLR < 2.06) was higher than those with higher NLR (NLR≥ 2.06) (24.5 % vs.14.3 %, p < 0.05). Those patients with higher
pretreatment NLR (NLR≥ 2.1) had more advanced stages of cancer and higher disease-specific mortality. Through a
multivariate analysis including all known predictive clinicopathologic factors, NLR≥ 2.1 was a significant independent
parameter affecting RFS (HR: 1.57, 95 % CI: 1.05-3.57, p < 0.05) and BCSS (HR: 2.21, 95 % CI: 1.01-4.39, p < 0.05). Patients
with higher NLR (NLR≥ 2.1) before treatment showed significantly lower relapse-free survival rate and breast
cancer-specific survival rate than those with lower NLR (NLR <2.1) (log-rank p= 0.0242 and 0.186, respectively).
Conclusions: Pretreatment NLR < 2.06 is associated with pCR rate, suggesting that NLR may be an important factor
predicting the response to NAC in breast cancer patients. NLR is an independent predictor of RFS and BCSS in breast
cancer patients with NLR≥ 2.1 who receive NAC. We suggest prospective studies to evaluate NLR as a simple prognostic
test for breast cancer.
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Background
Neoadjuvant therapy was initially used in patients with
inoperable locally advanced tumors. Neoadjuvant and adju-
vant administration of chemotherapy are equivalent in
terms of overall survival [1–4]. Neoadjuvant chemotherapy
used in patients with initially operable tumors is superior
for increasing the chance of achieving breast-conserving
surgery, evaluating the susceptibility of chemotherapy drugs
and assessing the response to chemotherapy. Patients with
a pCR after neoadjuvant chemotherapy have better disease-
free survival. The FDA recently granted accelerated ap-
proval for pertuzumab in combination with trastuzumab
and docetaxel as neoadjuvant treatment for patients with
Her-2-positive breast cancer as a result of the significant
improvement in pCR in patients. pCR has become an
important parameter in the approval of a new drug by
FDA, so it is important to find a clinical pathological indi-
cator to predict pCR in advance.
Predictive factors of the response to neoadjuvant chemo-
therapy include tumor size, pathology subtype, and differ-
entiation as well as expression of estrogen receptor (ER),
progesterone receptor (PR), human epidermal growth fac-
tor receptor 2 (HER2) and KI67 [5]. There is increasing
evidence that the neutrophil to lymphocyte ratio is associ-
ated with long-term outcomes, so this ratio has gained
much interest, with several studies over the last 5 years
investigating its role in predicting long-term outcomes in
various cancer populations, including lung, colorectal,
stomach, liver, and pancreatic cancer [6–10]. Based on
studies that show the association between high NLR and
increased mortality in breast cancer [11–13], we suggest
that NLR could be an important predictor of the response
to neoadjuvant chemotherapy as an inflammatory indicator.
The aim of the present study was to investigate the associ-
ation of NLR with pCR in patients who received neoadju-
vant chemotherapy and the prognostic value of NLR in
view of RFS and BCSS.
Methods
Data collections
We retrospectively identified 347 patients who were diag-
nosed with primary breast cancer and received NAC at Sun
Yat-sen Memorial Hospital between January 2001 and June
2010. The study was given ethical approval with Ethical
Committee of Sun Yat-sen Memorial Hospital and all the
patients had given written informed consent. The inclusion
criteria were as follows: (1) female aged 18 to 70, whose
expected survival time was more than 12 months; (2) clin-
ical stage II or III; (3) diagnosed with primary breast cancer
by core needle biopsy before NAC; (4) received 3 cycles or
more than 3 cycles of NAC after diagnosis and underwent
curative-intent surgery such as breast-conserving surgery
or modified radical mastectomy. Patients with ductal car-
cinoma in situ with or without microinvasion, patients with
missing information on pathologic or laboratory results,
and patients who were lost to follow-up were excluded.
We also excluded patients with stage IV breast cancer or
inflammatory breast cancer; patients who were diagnosed
preoperatively with systemic inflammatory or chronic dis-
ease, such as systemic lupus erythematosus (SLE), liver
cirrhosis, or end-stage renal disease; and patients with
pregnancy-related breast cancer.
Of these, 215 patients met the inclusion criteria. Medical
records were reviewed to find data on each patient’s
medical history, age, sex, chemotherapy regimen of NAC,
chemotherapy cycles of NAC, surgical method, pathologic
results (such as histologic type, tumor size, histological
grade, and lymph node status (number of positive lymph
nodes and all lymph nodes if axillary lymph nodes were
dissected), hormonal status, and HER2 receptor status),
and laboratory data (including C-reactive protein (CRP)).
The tumor size (T stage), lymph node status (N stage),
presence of metastasis (M stage) and the American Joint
Committee on Cancer (AJCC) stage for each patient were
obtained by reviewing the cancer registry data. T stage, N
stage and M stage before and after surgery are according to
AJCC [14].
We used taxane-based and/or anthracycline-based
chemotherapy regimens in neoadjuvant settings every
21 days: epirubicin and cyclophosphamide (EC, E: 90 mg/
m2, C: 600 mg/m2); docetaxel and cyclophosphamide (TC,
T: 100 mg/m2, C: 600 mg/m2); docetaxel, epirubicin and
cyclophosphamide (TEC, T: 75 mg/m2, E: 90 mg/m2, C:
500 mg/m2); and docetaxel, carboplatin and trastuzumab
(TCH, T: 75 mg/m2, C: AUC= 5, H: 8 mg/kg followed by
6 mg/kg). Trastuzumab was added if the tumor was posi-
tive for HER2 (but only 39 % of patients with Her-2 posi-
tive had taken Herceptin as adjuvant treatment because of
the high price). Neoadjuvant therapy, surgery, radiotherapy
and endocrine therapy were provided to patients according
to National Comprehensive Cancer Network (NCNN)
guidelines [14].
In all the patients, a routine blood test of peripheral vein
blood was performed immediately after breast cancer diag-
nosis and before the initiation of any treatment modality
(pretreatment NLR). NLR was calculated as the ratio of
absolute neutrophil count to absolute lymphocyte count in
this blood sample. A routine blood test was also taken right
before surgery (approximately 2-weeks after the last cycle
of NAC) so that the change in NLR from before to after
NAC could be calculated.
Pathology
We graded tumors according to the Scarff-Bloom-
Richardson [15] scheme. ER and PR status were assessed
by immunohistochemistry. ER and PR assays were consid-
ered positive if there were at least 1 % positive tumor
nuclei in the sample on testing in the presence of expected
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reactivity of internal (normal epithelial elements) and ex-
ternal controls [16]. HER2 status was assessed by immu-
nohistochemistry and/or fluorescent in situ hybridization
(FISH). It was considered positive if the score was 3 with
immunohistochemistry or there were at least 2.2 times as
many HER2 signals as CEP 17 signals in the tumor cells.
Molecular subtype was divided into 4 groups according
to the immunohistochemical staining for ER, PR, HER2
and KI67 [17]: luminal A subtype, ER-positive and/or PR-
positive and HER2-negative, KI67 < 14 %; luminal B sub-
type, ER-positive and/or PR-positive and HER2-positive, or
ER-positive and/or PR-positive and HER2-negative, KI67 ≥
14 %; HER2-enriched subtype, ER- and PR-negative with
positive HER2; triple-negative tumors, ER-negative, PR-
negative and HER2-negative.
Assessing chemotherapy response
Clinical remission was assessed for primary tumors through
physical examination and ultrasonic measurement after all
cycles of NAC before surgery. The response to neoadjuvant
chemotherapy was according to the NSABP criteria [18] for
therapeutic effect evaluation: clinical complete response
(cCR): the absence of clinical evidence of tumor in the
breast; clinical partial response (cPR): the product of the
two largest perpendicular diameters of the breast tumor
had decreased by 50 % or more; stable disease (cS): patients
whose breast tumor did not meet the criteria for cCR, cPR,
or cP ; progressive disease (cP): there was a 50 % or greater
increase in tumor size. Pathological therapeutic effect was
assessed for resected primary tumors after surgery. pCR
was defined as the absence of all invasive disease in the
breast tumor and no residual tumor in axillary lymph nodes
for histopathological therapeutic effect [19, 20].
Clinical outcomes
A relapse event is defined as any local relapse and distant
relapse including invasive ipsilateral breast tumor recur-
rence, ipsilateral DCIS, local invasive recurrence, regional
invasive recurrence and appearance of metastases. RFS is
defined as time before any relapse event according to
DATECAN guidelines for breast cancer [21]. And BCSS
were calculated from the date of diagnosis until the date
the patient succumbed to the disease or the last follow-up
time. Patients who succumbed to unrelated causes with
no evidence of disease were censored.
Follow-up
The presence of a relapse event was determined by means
of imaging modalities, including CT, MRI, US, SPECT,
PET-CT and biopsy of suspicious lesions. The patients
underwent at least one type of imaging examination at in-
tervals of 3–4 months during the first 2 years after surgery,
and at intervals of 4–6 months thereafter until 5 years after
surgery, and at intervals of 12 months after 5 years since
surgery.
Statistical analyses
The capacity of NLR in predicting relapse events was ana-
lyzed using receiver operating characteristic (ROC) curve
analysis. The T test (or Mann-Whitney U test) and
Wilcoxon rank sum test were used for comparing the
differences of variables between two groups, when appro-
priate. All the continuous variables are expressed as the
median (Q1 [25th percentile] - Q3 [75th percentile]) value.
The association between NLR and pCR was evaluated using
the chi-square test. We used the Kaplan-Meier Method
and Cox proportional hazard model as univariate and
multivariate analysis, respectively. In all analyses, differ-
ences were considered significant at p < 0.05. Statistical ana-




We identified 347 patients who were diagnosed and com-
pleted the treatment for breast cancer, and 215 patients
were eligible for analysis. The baseline characteristics of
the study subjects are summarized in Table 1.
The median value of pretreatment NLR was 2.05 (range,
0.45-15.04). Of the total of 215 patients, 111 (51.6 %) pa-
tients had NLR less than 2.1. A NLR greater than or equal
to 2.1 was associated with increased T stage, TNM stage,
relapse events, higher CRP value, and breast cancer specific
mortality (Table 2). Therefore, patients in the higher NLR
group before treatment tended to have higher staging and
worse survival.
ROC analysis showed that if the chosen cut-off point for
NLR was 2.1, the specificity and sensitivity were 55.7 %,
66.7 %, respectively. These were statistically signifi-
cant (p < 0.05; AUC = 0.598, 95 % CI: 0.511-0.686)
(Additional file 1: Figure S1).
Higher NLR before treatment was associated with
higher CRP. However, there was no significant correl-
ation between CRP value and NLR (Pearson correlation
coefficient 0.324, p = 0.068, Additional file 2: Figure S2).
Association between NLR and pathologic response
An increased pCR rate was observed primarily in those
patients with lower NLR before treatment. The overall
pCR rate was 19.5 % (42 of 215 patients). Patients in the
NLR < 2.06 group showed significantly higher pCR rate
than did patients in the NLR ≥ 2.06 group (NLR < 2.06 vs.
NLR ≥ 2.06, 24.5 % vs. 14.3 %, p < 0.05, χ2 test) (Fig. 1).
We performed univariate and multivariate analysis in-
cluding pCR with established clinicopathologic parameters.
As shown in Tables 3 and 4, the percentage of pCR was a
significant independent parameter, with a hazard ratio (HR)
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for pCR of 1.53 (95 % CI: 1.09 to 5.65, p < 0.05) in RFS as
well as BCSS (HR: 3.37, 95 % CI: 1.93 to 28.26, p < 0.05)
(Table 4).
Relapse-free survival and breast cancer-specific survival
by NLR status
Kaplan–Meier curves showed significantly higher (log-rank
p < 0.05) relapse-free survival and breast cancer-specific
survival in the lower NLR group before treatment (NLR <
2.1) compared with the higher NLR group (NLR ≥ 2.1)
(Fig. 2).
With a median follow up of 55 months, 39 (18.1 %)
and 32 (14.9 %) patients had relapse events and death
events, respectively. In univariate analysis, pretreatment
NLR; CRP value; advanced T, N, and AJCC stages; HG
and pCR after NAC were all associated with RFS and BCSS.
Higher NLR was associated with decreased RFS and BCSS
(respectively: HR: 2.11, 95 % CI: 1.09-4.11, p < 0.05; HR:
2.45, 95 % CI: 1.13-5.31, p < 0.05) in our univariate analysis
(Table 3). Next, pTNM stage, HG, hormone receptor, pCR,
Table 1 The characteristics of 215 patients with breast cancer
Characteristic No. (%)








T stage c Ta p Ta
T0-T1 3 (1.4) 131(60.9)
T2 108(50.2) 64(29.8)
T3 84 (39.1) 7(3.3)
T4 20 (9.3) 13(6.0)
N stage c Na p Na
N0 46 (21.4) 89(41.4)
N1 108 (50.2) 55(25.6)
N2 43 (20.0) 43(20.0)
N3 18 (8.4) 28(13.0)




















Luminal A 120 (55.8)




























Mean 57.6 ± 27.1
Range 36.1, 75.8
acT, cN, cTNM are clinical stages before NAC. pT, pN, pTNM are pathological
stages after surgery
EC epirubicin and cyclophosphamide, TC docetaxel and cyclophosphamide,
TEC docetaxel, epirubicin and cyclophosphamide, TCH docetaxel, carboplatin
and trastuzumab
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operation method, NLR and CRP were incorporated into
the multivariate analysis, which further confirmed that
NLR before treatment was an independent risk factor for
RFS and BCSS, with respective HRs of 1.57 (95 % CI: 1.05-
3.57, p < 0.05) and 2.21 (95 % CI: 1.01-4.39, p < 0.05), re-
spectively. We did not include T-stage because there might
be colinearity between T-stage and TNM-stage (Table 4).
Discussion
In this study, we examined a cohort of breast cancer pa-
tients who received neoadjuvant chemotherapy to provide
evidence on the predictive value of pathologic complete re-
sponse and the prognostic value of NLR. The main finding
of our analysis is that high pretreatment NLR was associ-
ated with pCR and was a significant independent predictor
of RFS and BCSS in breast cancer patients undergoing pre-
operative chemotherapy.
To date, few studies have examined whether pretreat-
ment NLR is predictive for pCR. Only one study has deter-
mined the relationship between pCR and pretreatment
peripheral blood NLR in patients who had NAC for locally
advanced BC. In that study, Eryilmaz et al. [22] showed no
relationship between pCR and pretreatment NLR value, in
contrast to our results. To our knowledge, this is the first
time that a strong association between pretreatment NLR
and chemotherapy response is described in a breast cancer
study. Our results demonstrate that patients with NLR ≥
2.06 showed poor response to neoadjuvant chemotherapy
(Fig. 1). Patients with NLR < 2.06 showed a higher pCR rate
than those with NLR ≥ 2.06. The major causes of these con-
trasting findings may be the insufficient sample size (only
78 patients) and nonstandardized therapies (some patients
had anthracycline-taxane based, some had hormonal-based
NACs) in the study by Eryilmaz et al. [22]. For this reason,
our results are more reliable. A lower NLR value (<2.06) is
more likely to reach pCR, and it is useful in consultation
for patients and clinical decision-making.
Patients showing a pCR to neoadjuvant chemotherapy
enjoy prolonged disease-free survival [23], which corrobo-
rates our finding that patients with NLR < 2.1 showed a
relatively better prognosis. Meanwhile, an elevated pretreat-
ment NLR is associated with worse RFS and BCSS. We
found that elevated NLR at initial clinical presentation of
breast cancer was an independent factor for poor survival
rate in breast cancer patients. This finding is consistent
with previous reports in several other cancers as well as
breast cancer [6, 8–10, 24, 25]. A higher NLR (NLR > 3.3)




<2.1 (n = 111) ≥2.1 (n = 104) P
No. (%) No. (%)
Age (yr)a 215 45.4 ± 9.3 47.5 ± 10.2 NS
cTb 215 <0.05
1 2 (1.8) 1 (1.0)
2 66 (59.5) 42 (40.4)
3 36 (32.4) 48 (46.2)
4 7 (6.3) 13 (12.5)
cNb 215 NS
0 25 (22.5) 21 (20.2)
1 61 (55.0) 47 (45.2)
2 18 (16.2) 25 (24.0)




2 67 (60.4) 41 (39.4)
3 44 (39.6) 63 (60.6)
HG 215 NS
1 36 (32.4) 32 (30.8)
2 51 (45.9) 42 (40.4)
3 24 (21.6) 30 (28.8)
ER 215 NS
- 27 (24.3) 38 (36.5)
+ 84 (75.7) 66 (63.5)
PR 215 NS
- 39 (35.1) 34 (32.7)
+ 72 (64.9) 70 (67.3)
HER2 215 NS
- 68 (61.3) 70 (67.3)
+ 43 (38.7) 34 (32.7)
ER+ and/or PR+ 174 93 (83.8) 81 (77.9) NS
ER− PR− 41 18 (16.2) 23 (22.1)
Molecular subtype 215 NS
Luminal A 62 (55.9) 58 (55.8)
Luminal B 30 (27.0) 22 (21.2)
HER2-enriched 12 (10.8) 13 (12.5)
Triple-negative 7 (6.3) 11 (10.6)




No 176 98 (88.3) 78 (75.0)
Yes 39 13 (11.7) 26 (25.0)
Table 2 Baseline characteristics by NLR (Continued)
Death <0.05
No 183 102 (91.9) 81 (77.9)
Yes 32 9 (8.1) 23 (22.1)
aMean ± SD. bcT, cN, cTNM are clinical stages before NAC
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has been correlated with an advanced stage of breast cancer
[12]. Additionally, higher-NLR patients (NLR > 2.5), espe-
cially with the luminal A subtype, show significantly poorer
prognosis than lower-NLR patients [13]. Previous studies
included patients irrespective of whether they received
NAC, whereas we only focused on patients who received
NAC. Azab et al. [12] used the 75th NLR percentile as the
NLR cutoff, while Noh [13] used receiver operating charac-
teristic (ROC) curve analysis to determine the NLR cutoff.
Our study also used ROC curves to determine the cutoff,
and our NLR cutoff was 2.11. Regardless of these differ-
ences, the results from our study appear to favor the same
conclusion: that patients with an elevated pretreatment
NLR show poorer disease-specific survival than patients
without elevated NLR.
The association between an elevated NLR and poor
prognosis is complex. Increasing evidence suggests that
cancer progression is influenced by the systemic inflam-
matory response [26]. Components of this inflammatory
response are associated with patients’ prognostic out-
comes. An elevated NLR is due to a relative neutrophilia
and lymphocytopenia that occurs as part of the systemic
inflammatory response triggered by cancer [27–30]. First,
neutrophils may inhibit immune system function. Neutro-
phils promote remodeling the extracellular matrix, which
promotes tumor growth and metastasis via its enzymatic
actions, including the release of reactive oxygen species
(ROS), nitric oxide (NO), and anginas [31–33]. In
addition, relative neutrophilia enhances tumor growth and
progression by activating inflammatory markers that in-
clude pro-angiogenic factors (VEGF), growth factors
(CXCL8), proteases and anti-apoptotic markers (NF-kB)
[9, 12, 34, 35]. In breast cancer, neutrophil-derived oncos-
tatin M signals human breast cancer cells to secrete VEGF
and increases breast cancer cells’ detachment and inva-
siveness [36]. On the other hand, lymphocytic response is
the main component of controlling cancer progression.
Increased lymphocyte infiltration has been correlated with
higher pCR rate and a better prognosis in breast cancer
patients who received neoadjuvant chemotherapy [37–39].
Lymphocytes (especially T4 helper and T8 suppressor
lymphocytes) decline markedly in the cell-mediated im-
mune system [29]. Moreover, immune modulators, includ-
ing TGF β, IL10 and CRP, released by tumor cells impair
lymphocyte action in systemic inflammation [40]. Tumor-
infiltrating lymphocytes such as natural killer and T helper
type 1 are effective components against cancer growth
and/or metastasis in several cancers via their production
of interferon gamma [41]. Chemotherapy might be an
effective immunotherapy against such tumor types, and
the combined effect of chemotherapeutic destruction of
tumor cells and increased immune response may result in
a pCR [39, 42]. Thus, a low lymphocytic infiltration at
tumor margins corresponds with a poorer prognosis [27,
43, 44].
In this study, patients in the higher pretreatment NLR
group tended to have higher staging. This corroborates
previous reports that these preoperative characteristics
Fig. 1 Percentages of pCR in patients stratified by NLR. In the chi-square test, the patients were divided into two groups based on the NLR cutoff
(NLR < 2.06 group and NLR≥ 2.06 group). Patients in the NLR < 2.06 group showed significantly higher pCR rate than did patients in the NLR≥
2.06 group (p < 0.05)
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Table 3 Hazard ratios of baseline characteristics for RFS and BCSS (univariate analysis)
RFS BCSS
Variable No. Hazard ratio (95 % CI) P Hazard ratio (95 % CI) P
Age 215 1.16 (0.46–2.98) NS 1.11 (0.39–3.16) NS
pT stagea 215
T0 1.0 1.0
T1 1.58 (0.46–5.46) NS 1.54 (0.34–7.06) NS
T2 2.12 (0.61–7.37) NS 2.30 (0.51–10.41) NS
T3 7.80 (1.74–34.97) <0.01 11.29(2.06–61.89) <0.01
T4 2.64 (0.53–13.10) NS 8.95 (1.73–46.29) <0.01
pN stagea 215
N0 1.0 1.0
N1 1.77 (0.66–4.74) NS 2.38 (0.69–8.23) NS
N2 and N3 2.75 (1.01–7.56) <0.05 4.61 (1.32–16.08) <0.05
pTNMa 215
0–1 1.0 1.0
2 1.15 (0.41–3.22) NS 1.63 (0.50–5.30) NS
3–4 3.41 (1.39–8.35) <0.01 3.92 (1.33–11.54) <0.05
HG 215
1 1.0 1.0
2 2.68 (0.56–12.89) NS 1.65 (0.30–9.01) NS
3 26.29(6.25–10.57) <0.001 21.70(5.11–92.12) <0.001
Hormone receptor 215
ER+ PR+ 1.0 1.0
ER+ or PR+ 1.88 (0.93–3.82) NS 2.05 (0.94–4.50) NS
ER− PR− 1.76 (0.76–4.08) NS 1.95 (0.77–4.89) NS
Her2 215
+ 0.84 (0.43–1.66) NS 1.14 (0.56–2.34) NS
- 1.0 1.0
Molecular subtype 215
Luminal A 1.0 1.0
Luminal B 1.12 (0.53–2.39) NS 1.32 (0.58–3.00) NS
HER2-enriched 0.81 (0.24–2.71) NS 1.04 (0.30–3.58) NS
Triple-negative 2.07 (0.78–5.50) NS 2.11 (0.70–6.33) NS
pCR 215
Yes 1.0 1.0
No 3.00 (1.92–9.73) <0.05 9.05 (1.24–65.97) <0.05
Chemotherapy regimen 215
TEC 1.0 1.0
TCH 0.89 (0.67-2.93) NS 1.65 (0.54-3.42) NS
TC 1.19 (0.86–2.25) NS 1.32 (0.42–2.91) NS
EC 1.23 (0.63–2.40) NS 1.20 (0.58–2.48) NS
Surgery 215
Breast-conserving surgery 1.0 1.0
Modified mastectomy 0.55 (0.27–1.10) NS 0.46 (0.21–1.03) NS
Chemotherapy cycles 215
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are associated with vascular invasion and a more aggres-
sive phenotype [44–46]. Stage is directly representative
of tumor progression and is subsequently reflective of
the immune response (neutrophilia and lymphocytope-
nia), and it is not surprising that higher stages corres-
pond to higher NLR and therefore worse survival [43].
There was a significant discordance of NLR cutoffs
used in previous studies [47]. Most of the studies have
used an NLR of 5 as the cutoff based purely on previous
work. Only four studies used ROC sensitivity and speci-
ficity analyses to determine an NLR cutoff. Azab et al.
[12] used 75th NLR percentile as the NLR cutoff. Al-
though most studies used NLR > 5 as the cutoff, this
does not imply that patients with an NLR < 5 were not
at an increased risk. In fact, several other studies demon-
strated NLR ranges of 4 and below (even as low as 1.9)
as having prognostic significance in overall survival [47].
We used ROC curve analysis to determine the NLR cut-
off. ROC curve analysis suggested that the optimum
NLR cut-off point was 2.11 (AUC: 0.589, 95 % CI: 0.511-
0.686, p < 0.05) with a sensitivity of 66.7 % and specificity
of 55.7 %. Pichler et al. [48] mentioned that the ideal cutoff
Table 4 Cox proportional multivariate hazard model for relapse-free survival and breast cancer-specific survival
RFS BCSS
Variable No. Hazard ratio (95 % CI) P Hazard ratio (95 % CI) P
pTNMa 215
0–1 1.0 1.0
2 1.77 (0.89–3.53) NS 1.36 (0.49–3.80) NS
3–4 4.09 (1.69–9.90) <0.05 3.37 (1.30–9.31) <0.05
HG 215
1 1.0 1.0
2 2.35 (0.47–11.72) NS 1.84 (0.32–10.52) NS
3 26.98(5.82–125.12) <0.001 19.21 (4.15–88.90) <0.001
Hormone receptor 215
ER+ PR+ 1.0 1.0
ER+ or PR+ 1.53 (0.70–3.33) NS 1.63 (0.74–3.57) NS
ER− PR− 3.31 (1.28–8.58) <0.05 2.94 (1.17–7.41) <0.05
pCR 215
Yes 1.0 1.0
No 1.53 (1.09–5.65) <0.05 3.37(1.93–28.26) <0.05
Surgery 215
Breast-conserving surgery 1.0 1.0
Modified mastectomy 0.80 (0.33–1.92) NS 0.77 (0.29–2.05) NS
NLR (before NAC) 215
NLR < 2.1 1.0 1.0
NLR≥ 2.1 1.57 (1.05–3.57) <0.05 2.21 (1.01–4.39) <0.05
CRP (before NAC) 215 1.02 (0.99–1.05) NS 1.00 (0.97–1.04) NS
apT, pN, pTNM are pathological stages after surgery
Table 3 Hazard ratios of baseline characteristics for RFS and BCSS (univariate analysis) (Continued)
3 1.0 1.0
4 1.15 (0.52–2.54) NS 1.07 (0.47–2.48) NS
>4 0.64 (0.17–2.42) NS 0.76 (0.20–2.88) NS
NLR 215
NLR < 2.1 1.0 1.0
NLR≥ 2.1 2.11 (1.09–4.11) <0.05 2.45 (1.13–5.31) <0.05
CRP (before NAC) 215 1.03 (1.01–1.05) <0.001 1.03 (1.01–1.06) <0.01
apT, pN, pTNM are pathological stages after surgery. EC epirubicin and cyclophosphamide, TC docetaxel and cyclophosphamide, TEC docetaxel, epirubicin and
cyclophosphamide, TCH docetaxel, carboplatin and trastuzumab
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Fig. 2 Kaplan-Meier estimates for RFS and BCSS stratified by NLR. The patients were divided into two group based on the NLR cutoff (NLR < 2.1group
and NLR≥ 2.1 group). a. Relapse-free survival in the patients based on the NLR cutoff (p < 0.05). b. Breast cancer-specific survival in the patients based
on the NLR cutoff (p < 0.05)
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value for a continuous NLR was calculated by testing all
possible cutoffs that would discriminate between survival
and cancer-related death by Cox proportional analysis. We
tested all possible cutoffs in this way from 2.0 to 2.9, and
the ideal cutoff value was 2.1 for survival as well as 2.06 for
pCR+ and pCR− patients. Most studies focus on different
tumors, which tend to have different inflammatory status.
Even in breast cancer patients, different age, stage and
phenotype correspond with different immune response and
therefore different NLR.
Additionally, we are interested in the relationship be-
tween the change in NLR (ΔNLR) and its relationship with
pCR or relapse-free survival. We found no significance in
the relationship between ΔNLR and pCR or RFS (data not
shown). Different chemotherapy regimens may lead to dif-
ferent degrees of neutropenia, as anthracycline and taxane-
based regimens can cause severe neutropenia. Patients with
neutropenia after NAC were suggested to take granulocyte
colony-stimulating factors (G-CSF) to stimulate the release
of leucocytes, which may also have affected neutrophil and
lymphocyte counts. That would result in different baseline
NLR after NAC. So we believe that the pretreatment NLR
is likely to be the most robust NLR value to use.
The major limitation of our study is the retrospective
nature. Many patients whose records lacked information or
who were lost to follow-up were not enrolled in the study,
and that may have led to selection bias. Second, it was be-
yond the scope of this study to make clear whether patients
with Her-2 positive tumors had taken Herceptin as adju-
vant treatment because not all the patients could afford the
high price before 2010 in China. This might have had some
statistical influence on survival because Herceptin has made
such an enormous impact, particularly on disease-free
survival. Third, patients with different ages, stages and phe-
notypes corresponded to different immune responses, and
we were not able to conduct a stratified analysis on such
small subgroups of patients. Moreover, our study lacked
any evaluation of tumor-associated neutrophils and lym-
phocytes. Furthermore, analysis about local recurrence-free
survival and metastasis-free survival relating to long-term
outcome were limited by the patients’ records. Besides, fur-
ther study into the relationship between tumor-infiltrating
lymphocytes and NLR is needed to validate our results.
The aforementioned limitations taken together with the
relatively small sample size suggest that our results
need to be validated in additional independent cohorts
of breast cancer patients, ideally through large-scale
prospective clinical studies.
Pretreatment NLR represents a simpler, more robust and
more convenient parameter compared with other patho-
logical indicators, such as KI67. The use of pretreatment
NLR may facilitate the administration of NAC therapy in
patients with lower NLR to reach a better pCR rate and to
enhance long-term outcomes.
Conclusions
Our findings suggest that NLR is an important factor
predicting the response to NAC in breast cancer patients.
Patients with higher NLR showed a lower percentage of
pCR after NAC, and high NLR was an independent signifi-
cant predictor of lower RFS and BCSS in breast cancer pa-
tients. Further prospective, multicenter studies are needed
to validate our results.
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